Proactive Investors - Run By Investors For Investors

Dechra Pharmaceuticals makes bolt-on acquisition

It is paying £4.4mln or 2.4-times revenues for Caledonian Holdings
Dechra Pharmaceuticals makes bolt-on acquisition
The UK group is buying a New Zealand supplier to vets specialising in horses

Dechra Pharmaceuticals PLC (LON:DPH) has made a small bolt-on acquisition.

It is paying £4.4mln or 2.4-times revenues, for Caledonian Holdings, a New Zealand supplier to vets specialising in horses.

The deal will establish Dechra as a leading equine pharmaceutical supplier in both Australia and New Zealand, the company said.

"We are pleased to have acquired the trade and assets of Caledonian which will be integrated into our existing Australian and New Zealand businesses. This will enable Dechra to leverage its position in the ANZ equine market," said chief executive Ian Page.

 

View full DPH profile View Profile

Dechra Pharmaceutical Timeline

Related Articles

pippette
November 23 2018
The Australian regenerative medicine company is developing a portfolio of innovative cellular therapies targeting significant unmet medical needs with a licence-driven strategy.
1537236236_main-better-use.jpg
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
blood
December 03 2018
Feraccru already has EU approval while in Switzerland the drug can be used for iron deficiency anaemia in adults with inflammatory bowel disease

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use